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Chalcones are open chain molecules precursors of flavonoids and isoflavonoids, found spread in edible plants. Because they are 
easily accessible trough Claisen Shmidt condensation, a great variety of derivatives are available. They have also shown potential 
in pharmacological and biological applications. It is known that chalcone derivatives display a role in the treatment of complex 
diseases such as cancer, among others, where the DNA is considered as the target for the action of these kinds of compounds. 
This action is commonly explained as the inhibition of the DNA replications and transcriptions through interactions. However, not 
conclusive associations between these DNA-Drug interactions and toxicity have been found. This research focuses on the capacity of 
a chalcone`s family to interact with DNA. Therefore, the binding constants for each compounds with Calf Thymus DNA [CT-DNA] 
were determined by spectrophotometric titration at room temperature. In addition, the effect of increasing the chalcone`s concentration 
over the relative viscosity of CT-DNA at room temperature was assessed. On the other hand, with the aim to find the optimal DNA-
chalcone configurations, as well as consistently predict their binding, a computational work was undertaken. To accomplish these goals 
within a reasonable time framework, an empirical scoring function (AScore) and a docking engine (ShapeDock) were performed using 
the ArgusLab package. The results of viscosity and docking measurement provided structural insights which suggest that chalcones 
bind with DNA via interaction as well as intercalation. The presence of interactions is also evidenced by the spectrophotometric study 
which showed luminescence quenching of the chalcones upon interaction with CT-DNA.
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INTRODUCTION 
Chalcones are open chain molecular systems precursors of flavo-
noids1 and isoflavonoids, present frequently in edible plants. 
Structural modification of chalcones has allowed to obtain deri-
vatives which display potential and worthy applications in pharmaco-
logical and biological areas like new medicinal agents with improved 
properties, such as higher potency and lesser toxicity.2
This wide range of biological activities associated with many 
chalcone derivatives, has stimulated interest in the development of 
synthetic strategies aimed to the synthesis of heterocyclic systems 
starting from chalcones. Besides of the implementation of efficient 
methodologies for their obtaining, researches have focused also on 
the study of their reactivity and the assessment of their possible 
biological activities.3–5
Particularly in the pharmaceutical field, chalcone derivatives have 
found application on the treatment of different important diseases 
such as cancer, among others.6–10
DNA is thought to be the main target of antitumoral drugs, and 
the binding between cisplatin complexes and DNA targets have been 
extensively studied.11,12 Authors have shown that DNA interactions 
with several compounds affect the replication process and hence this 
inhibits the growth of the tumor cells, this means antitumor effects.
This effect has been the basis for designing new and more efficient 
antitumor drugs. Moreover, their effectiveness depends on the mode 
and affinity of their binding ability to the DNA strands.13
The interactions between DNA and drugs has been considered as 
the main aspect that govern the DNA replications and transcription in 
cancer cells.14 It should be considered though, that not deep studies of 
DNA-Drug interactions and their toxicity have been performed.15–17 
This research focuses on the capacity of a chalcone’s family 
(Figure 1) to interact with DNA. Therefore, the binding constants 
for the chalcone complexes with CT-DNA were determined by 
spectrophotometric titration at room temperature. These procedures 
were performed through the stepwise addition of a CT-DNA solu-
tion to a chalcone solution. In addition, the effect of the increasing 
chalcone’s concentration over the relative viscosity of CT-DNA at 
room temperature was assessed.18,19
EXPERIMENTAL
Docking
The docking procedure is envisaged as a complex optimization 
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or an exhaustive search process since it involves many degrees 
of freedom. The ultimate goal is to find the optimal ligand/DNA 
configurations, and to predict their binding free energy. To compu-
tationally accomplish this key objective within a reasonable time 
framework, an empirical scoring function (AScore) and a docking 
engine (ShapeDock) were employed in the ArgusLab program.20
The AScore is based on the deconvolution of the total DNA-ligand 
binding free energy into different components:
∆Gbinding = ∆GvdW + ∆Ghydrophobic + ∆GH-bond + ∆GH-bond(chg) +  
∆Gdeformation + ∆G° 
The dissected terms account for the van der Waals interaction 
between the ligand and the DNA (∆GvdW), the hydrophobic effect 
(∆Ghydrophobic), the hydrogen bonding between the ligand and the protein 
(∆Ghydrophobic), the hydrogen bonding involving charged donor and/or 
acceptor groups (∆GH-bond(chg)), the deformation effect (∆Gdeformation), 
and the effects of the translational and rotational entropy loss in the 
bidding process (∆G°).
The 3D structures of chalcones were first constructed using 
Arguslab , then were optimized using Austin Model 1 [AM1] , 200 
maximum iteration , followed by conjugate gradient minimization to 
a RMS energy gradient of 0,01 kcal/mol.21 Candidate conformations 
of Chalcones interacting to their target structures, the DNA complex, 
were proposed using Arguslab.22,23 Here, docking was carried out with 
a set of Chalcones. (Figure 1)
Chemicals 
Synthesis of Chalcones, general methodology: Chalcones were 
prepared by adding dropwise a solution of the corresponding substitu-
ted benzaldehyde, (7.34 mmol in ethanol, 20 mL) to a stirred mixture 
of 2-hydroxyacetophenone solution (7.34 mmol, in ethanol, 20 mL) 
and potassium hydroxide solution (2 g in 10 mL distilled water). 
The mixture was allowed to react overnight, and then, distilled water 
(200 mL) were added and neutralized with hydrochloric acid. Then, 
the mixture was extracted four times with ethyl acetate (50 mL). The 
combined organic fractions were concentrated in vacuum, dissolved 
in ethanol, and allowed to crystallize.
We have previously described the synthesis of the following 
compounds: 2,3,4’-trimethoxy-2’-hydroxy-chalcone (1)1 which 
was obtained as orange crystals (58%), mp. 129–130°C; 2,4-di-
methoxy-2’-hydroxy-chalcone (2)1,7,24 obtained as yellow crystals 
(58%), mp. 107 – 109.8 °C; 3´-bromo-3,4-dimethoxy-chalcone (3)25 
obtained as yellow crystals (73%), mp.117–120 °C; The following 
compounds were prepared as previously reported in the literature. 
Spectroscopic data were identical to those previously reported: 
2,5,4´-trimethoxy-2’-hydroxy-chalcone (4)9 obtained as orange crys-
tals (75%) mp. 107 - 108 °C and 4’-methoxy-2,4-dichloro-chalcone 
(5)26 obtained as white crystals (69%), mp. 136.1 - 137.4 °C.
Cell culture
HUVEC-derived endothelial cell line, (EA.hy926) was kindly 
provided by C-J Edgell and was grown in Dulbecco´s modified Eagle 
Medium (DMEM)-low glucose (GIBCO) supplemented with 10% 
heat-inactiva fetal bovine serum (FBS), 2 mmol L-1 and 50 U mL-1 
penicilin/streptomycin (Sigma). 
Human hepatocellular carcinoma HepG2 cells (American Type 
Culture Collection HB-8065) were grown in monolayer culture 
in DMEM-high glucose with 10% FBS and antibiotic-antimicotic 
(GIBCO). All cell cultures were grown at 37 °C in a 5%: 95% CO2: 
air atmosphere controlled.
Cell viability assay 
Cell viability was evaluated using the 3-(4,5-dimethylthiazol-2-
-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay 
(Invitrogen, Eugene, Oregon, USA). Cell viability was quantified by 
the amount of MTT reduction27 HepG2 and EA.hy926 were exposed 
to different concentrations of chalcones for 48 hours. After treatment 
cells were co-incubated with MTT (0.5 mg mL) for 4 hours, and then 
solubilized with an acidified (0.04 N HCl) isopropanol/dimethyl sul-
foxide (DMSO) solution. Optical density was measured at 540 nm. 
All experiments were performed as triplicates. Data were expressed 
as percentage of survival cell. Cell survival (%) data were plotted 
and adjusted to a sigmoidal best-fit curve, where: IC50 is the chalcone 
concentration to reach the half-maximal cell survival. 
Interaction of chalcones with CT-DNA by spectrophotometric 
titration
Absorption spectroscopy is a useful tool to study the binding of 
drugs to DNA. Increments in DNA concentration result in shifts of 
absorption bands, which denote an effect of hyperchromism, resulting 
from a direct interaction between CT-DNA and the chalcones. These 
changes are similar to those small molecules that bind to double-
-stranded DNA through noncovalent interactions28,29
In this sense, the binding constants for the chalcone compounds 
with CT-DNA were determined by absorption titration at room 
temperature through the stepwise addition of a CT-DNA solution 
(10 μL, ∼4×10-4 mol L-1) to a solution of each chalcone (2 mL 
of (1) 4.8×10-5 mol L-1, (2) 4.8×10-5 mol L-1, (3) 5.6×10-5 mol L-1, 
(4) 4.8×10-5 mol L-1 and (5) 4.8×10-5 mol L-1) in buffer Tris/HCl and 
NaOH adjusted to pH 7.39. 
UV-vis absorption spectra were recorded between 190-1000 nm 
and the titration was finished when the intensity of those two bands 
did not change significantly upon further addition of CT-DNA. The 
binding constant Kb was calculated by using the Scatchard equation:
   (1)
where [DNA] is the concentration of DNA, εa is the molar absorption 
coefficient of the complex chalcone-DNA at given DNA concentra-
tion, εf is the molar absorption coefficient of the solution of the free 
chalcone and εb is the molar absorption coefficient of the chalcone 
when fully bound to DNA. A plot of [DNA]/[εa-εf] vs [DNA] gives 
1/[εb-εf] as the angular coefficient. The Kb is determined by a ratio 
between the angular and the linear coefficients.
 
2´ 4´ 5´ 2 3 4 5 6
C1 OH OCH3 H OCH3 OCH3 H H H
C2 OH H H OCH3 H OCH3 H H
C3 H H Br H OCH3 OCH3 H H
C4 OH OCH3 H OCH3 H H OCH3 H
C5 H OCH3 H H H Cl H Cl
Figure 1. Chemical structures of the studied chalcones
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Viscosity
Hydrodynamic methods have been employed to test the binding 
mode of DNA to agents. In this sense, viscosity changes provide 
experimental advantages since viscosity is sensitive to length chan-
ges of DNA and the measures can reliably distinguish intercalation 
from groove binding. When intercalation is present, a planar ligand 
fragment is placed between adjacent base pairs, which induces leng-
thening of the helix. These interactions that result in the increase of 
the DNA length generate an increase of viscosity. On the other hand, 
a groove binder, typically carries out subtle changes and the DNA 
remains in the unperturbed form and not increase of the DNA length 
is observed, therefore this binding mode shows no increase of the 
viscosity of the DNA solutions.18,19
In the herein work, the effect of the increasing concentration of 
chalcones over the relative viscosity of CT-DNA at room temperature 
was measured employing a viscosimeter Anton Par Lovis 2000M. 
The values for relative specific viscosity (h/h0)1/3, where h0 is the 
specific viscosity contributions of DNA in absence of compound 
and h is the viscosity in the presence of the complex, were plotted 
against [complex]/[DNA] where [complex] is the concentration of 
the chalcones and [DNA] is the concentration of CT-DNA. 
RESULTS AND DISCUSSION 
The fact of inhibiting the replication process of DNA by action of 
drugs is the motivation of designing new and more efficient antitumor 
drugs. Moreover, their effectiveness depends on the mode and affinity 
of their binding ability to the DNA strands.13 It is for this reason that 
we employed two cell lines, which have different DNA replication 
rate, where HepG2 cells have a high rate of replication with respect 
to EA.hy296 cells. The interactions of chalcones with DNA may have 
a crucial relevance in its induction of tumor cell death. Our results 
showed a higher cytotoxic effect of chalcones in EA.hy296 cells 
compared to HepG2 cells (Table 1). 
This selectivity of chalcones could be explained by a lower rate of 
DNA replication observed in EA.hy296 cells, however both lines are 
tumor and have low IC50, experiments in primary cultures of normal 
cells are necessary to determine their selectivity only to tumor cells. 
The IC50 and Kd values for the chalcone’s family studied here were 
compared in both cell lines. To compare the effect of chalcones on 
HepG2 and EA.hy296 cells, a correlation between IC50 and Kd 
was established (Table 1). The docking computations suggest that 
the chalcones does interact with DNA via intercalation and that the 
chalcones exhibits affinity for double stranded DNA as shown in 
Figure 2, such interaction with the nucleic acids could inhibit cellular 
DNA synthesis during DNA replication. 
According to this docking experiment, the complexes reasonably 
bind with DNA. The minimum energy obtained for a docked structure 
(Figure 2) suggest that the best possible conformation of the ligand 
Table 1. Relationship between IC50 [μM] ; HepG2 , EAhy926 , Kb and ΔG 
[kcal/mol]
Chalcone
EAhy.926 HepG2
dG 
[kcal mol-1] KbIC50 
[μmol L-1]
IC50 
[μmol L-1]
1 7.66 10.64 -4.06 2.33E+03
2 10.73 31.26 -4.06 2.33E+04
3 3.91 8.27 -4.04 3.33E+04
4 12.52 21.40 -3.98 3.75E+03
5 11.92 26.18 -4.13 2.58E+04
Figure 2. Molecular simulations of chalcones with DNA
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interaction, is mainly through the aromatic ring being inside the 
DNA strand. It has been observed that the complex is stabilized by 
electrostatic hydrogen bonding with DNA bases, in addition to van 
der Waal’s and stacking–bond interactions between electron deficient 
chalcone ring and purine–pyrimidine bases. The binding energy 
values are presented in Table 1.
Chalcones can bind with double-stranded DNA in various binding 
modes on the basis of its structure. However, hypochromic effect 
could be attributed to the stacking interaction between the aromatic 
rings of the ligand framework and DNA base pairs as well. The 
hypochromism and bathochromic shifts may commonly vary in con-
sistence with the strength of intercalative interaction of the complex 
with DNA helix as well as overall conformation of the DNA. The 
intrinsic binding constant of the chalcones with DNA was measured 
as Kb (see Methods). The low value of the binding constant obtained 
here (Kb = C1 2.33×103, C2 2.33×104, C3 3.33×104, C4 3.75×103, 
C5 2.58×104) suggests that the chalcones interacts with DNA double 
strand in an intercalated manner (Figure 3). 
On the other hand, taking into account the viscosity measure-
ments, on increasing the amounts of C4>C5>C1>C2>C3 bound to 
DNA, the relative viscosity of the DNA increases steadily (Figure 4). 
The observed linear increase in viscosity as a function of chalcone 
content for all compounds across the range of the relation of chalcone-
-DNA concentrations, suggests the fact that the interaction of the 
compounds with the DNA leads to increase the length of the DNA 
chains, which is indicative of the classical intercalation model.18,19 
Figure 3. Electronic titration spectra of chalcones with CD-DNA , a) C1, b) C2 , c) C3 , d) C4 , e) C5
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Finally, the results of UV-vis spectroscopy, viscosity and docking 
measurement showed that chalcones binds with DNA via intercala-
tion. It also suggests that the interactions of the chalcones caused a 
change in the conformation of DNA and thus an increase in inten-
sity of the antitumoral activity was generally observed. Moreover, 
the results described in this study showed that changing the ligand 
environment could modulate the binding property of the chalcones 
with DNA. 
CONCLUSIONS 
Three different approaches (spectrophotometric analysis, viscosi-
ty and molecular modeling) were considered to study the interaction 
between a family of chalcones and DNA.
After satisfactory spectroscopic measurements of the DNA 
binding ability with the studied compounds, molecular docking 
calculations were performed to understand the preferred orientation 
of sterically acceptable complexes.
Furthermore, increase in viscosity measured in the viscosity 
studies of chalcones-DNA complexes, helped to corroborate that the 
chalcones and DNA can interact via intercalation.
In general, the experimental and theoretical calculations indicated 
the presence of interactions between the chalcone’s family with CT-
DNA, which could explain the differences in cytotoxicity obtained 
in different cell types, since DNA replication is frequent in highly 
proliferating cells. 
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